ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,701.70
0.96%
S&P ASX All Technology
3,075.00
0.84%
Brent Oil
81.295
0.00%
US Dollar vs AUD
1.49858
-0.15%
Bitcoin
67,722.50
0.36%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pharvaris NV (PHVS)

  7. Pharvaris NV (PHVS) News

PHVS

Pharvaris NV (PHVS)

Pharvaris NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PHVS
DateTimeSourceHeadlineSymbolCompany
25/05/202407:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
23/05/202407:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
13/05/202420:50GlobeNewswire Inc.Pharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
09/05/202406:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
09/05/202406:10GlobeNewswire Inc.Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
11/04/202406:10GlobeNewswire Inc.Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
11/04/202406:08GlobeNewswire Inc.Pharvaris Appoints David Nassif, J.D., as Chief Financial OfficerNASDAQ:PHVSPharvaris NV
04/04/202421:50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceNASDAQ:PHVSPharvaris NV
18/03/202421:50GlobeNewswire Inc.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesNASDAQ:PHVSPharvaris NV
12/03/202404:51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
07/03/202408:40Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PHVSPharvaris NV
07/03/202408:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
06/03/202422:50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
05/03/202422:50GlobeNewswire Inc.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024NASDAQ:PHVSPharvaris NV
22/02/202422:50GlobeNewswire Inc.Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingNASDAQ:PHVSPharvaris NV
16/02/202422:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
16/02/202422:50GlobeNewswire Inc.Pharvaris Announces Extraordinary Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
08/02/202408:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
02/02/202408:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
26/01/202422:50GlobeNewswire Inc.Pharvaris to Present at the WSAAI Annual Meeting 2024NASDAQ:PHVSPharvaris NV
22/01/202423:35Dow Jones NewsPharvaris Says FDA Lifted Clinical Hold on Application for DeucrictibantNASDAQ:PHVSPharvaris NV
22/01/202422:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
22/01/202422:50GlobeNewswire Inc.Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
08/01/202423:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
05/01/202422:50GlobeNewswire Inc.Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesNASDAQ:PHVSPharvaris NV
03/01/202408:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
09/12/202310:00GlobeNewswire Inc.Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023NASDAQ:PHVSPharvaris NV
09/12/202308:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
08/12/202308:17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PHVSPharvaris NV
07/12/202308:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
 Showing the most relevant articles for your search:NASDAQ:PHVS

Your Recent History

LSE
CCR
C&c
NASDAQ
REVAX
RBC Emerging Markets Val...
LSE
JUES
Jpm Act Us Eq A
LSE
TI40
Orbta 22-1.29 A
COIN
APXPEUSD
AstroPepeX
USOTC
MTRC
Metaterra (PK)
BOV
P1KX34M
POSCO
BITV
BSVBTC
Bitcoin SV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved